HCW Biologics Inc. Receives Nasdaq Extension to Regain Compliance with Minimum Bid Price Rule
MIRAMAR, FL — May 29, 2026 — HCW Biologics Inc. (NASDAQ: HCWB) has announced a critical update regarding its continued listing on The Nasdaq Capital Market, following recent challenges related to its share price. This development is significant for investors and shareholders, as it directly affects the company’s status as a publicly traded entity on a major exchange.
Key Developments
- On March 26, 2026, HCW Biologics received a written notice from Nasdaq’s Listing Qualifications Staff that the company’s shares had failed to meet the minimum bid price requirement of \$1 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2), commonly referred to as the “Bid Price Rule.”
- Due to a 1-for-40 reverse stock split enacted on April 11, 2025, the company was not granted the standard 180-day grace period to regain compliance. This unusual circumstance heightened the risk of expedited delisting.
- After a hearing with the Nasdaq Hearings Panel on May 5, 2026, the company presented its compliance plan. On May 29, 2026, the Panel granted HCW Biologics an extension until July 29, 2026 to regain compliance with the minimum bid price rule.
- To satisfy Nasdaq’s requirements, the company’s share price must close at or above \$1 for at least twenty consecutive trading days by the deadline.
- If the company falls below the \$1 bid price before September 22, 2026, it will be immediately delisted. For other listing rule deficiencies, the company will have only seven calendar days to submit a cure plan to the Panel, which will then determine if further exceptions are warranted.
- If HCW Biologics regains compliance and satisfies the Panel’s conditions, a Discretionary Panel Monitor will be imposed for an additional year, as per Nasdaq Listing Rule 5815(d)(4)(A).
- The company is required to promptly notify Nasdaq of any significant events affecting its compliance status during this extension period.
Implications for Shareholders
- Share Price Volatility: The threat of delisting is a major risk factor that may cause significant fluctuations in the company’s share price as the July 29, 2026 deadline approaches.
- Reverse Stock Split Impact: The prior 1-for-40 reverse stock split underscores the company’s efforts to maintain its listing but also signals underlying challenges with share price performance and potential dilution for existing shareholders.
- Immediate Delisting Risk: Should the company fail to maintain the minimum bid price or violate other listing rules, delisting from Nasdaq could occur with limited notice, affecting liquidity and possibly leading to a sharp decline in share value.
- Panel Monitor Period: Even if compliance is regained, the company’s operations and reporting will be under heightened scrutiny for an additional year, which could impact investor confidence.
Investor Takeaways
This development is highly price sensitive. The company’s ability to regain and maintain compliance with Nasdaq’s minimum bid price rule is crucial for its continued listing and for preserving shareholder value. Investors should monitor upcoming trading activity and company announcements closely, as any failure to meet the specified requirements could result in delisting and a substantial loss of liquidity and value.
HCW Biologics At a Glance
- Business Address: 2929 N Commerce Pkwy, Miramar, FL 33025
- Trading Symbol: HCWB
- Exchange: The Nasdaq Stock Market LLC
- Entity Status: Emerging Growth Company (has elected not to use the extended transition period for complying with new or revised financial accounting standards)
Disclaimer: This article is for informational purposes only and is not investment advice. Investors should perform their own due diligence and consult with their financial advisors before making any investment decisions. The information provided is based on current disclosures and regulatory filings, and future developments could impact the company’s status and share value.
